NO20005481L - CD80-, CD86-, CD28- og CTLA-4-nukleinsyre og polypeptider fra katt - Google Patents

CD80-, CD86-, CD28- og CTLA-4-nukleinsyre og polypeptider fra katt

Info

Publication number
NO20005481L
NO20005481L NO20005481A NO20005481A NO20005481L NO 20005481 L NO20005481 L NO 20005481L NO 20005481 A NO20005481 A NO 20005481A NO 20005481 A NO20005481 A NO 20005481A NO 20005481 L NO20005481 L NO 20005481L
Authority
NO
Norway
Prior art keywords
feline
ctla
provides
nucleic acid
present
Prior art date
Application number
NO20005481A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005481D0 (no
Inventor
Ellen W Collison
Stephen M Hash
Insou Choi
Original Assignee
Texas A & M System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A & M System filed Critical Texas A & M System
Publication of NO20005481D0 publication Critical patent/NO20005481D0/no
Publication of NO20005481L publication Critical patent/NO20005481L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20005481A 1998-05-01 2000-10-31 CD80-, CD86-, CD28- og CTLA-4-nukleinsyre og polypeptider fra katt NO20005481L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7169998A 1998-05-01 1998-05-01
PCT/US1999/009502 WO1999057271A2 (en) 1998-05-01 1999-04-30 Feline cd80, feline cd86, feline cd28, and feline ctla-4 nucleic acid and polypeptides

Publications (2)

Publication Number Publication Date
NO20005481D0 NO20005481D0 (no) 2000-10-31
NO20005481L true NO20005481L (no) 2000-12-29

Family

ID=22102998

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005481A NO20005481L (no) 1998-05-01 2000-10-31 CD80-, CD86-, CD28- og CTLA-4-nukleinsyre og polypeptider fra katt

Country Status (20)

Country Link
EP (1) EP1073741B1 (de)
JP (3) JP2002513571A (de)
KR (2) KR20040053251A (de)
AT (1) ATE481485T1 (de)
AU (1) AU4070399A (de)
BR (1) BR9910153A (de)
CA (1) CA2327539A1 (de)
CZ (1) CZ20003935A3 (de)
DE (1) DE69942765D1 (de)
ES (1) ES2352745T3 (de)
HU (1) HUP0102806A3 (de)
IL (4) IL139371A0 (de)
NO (1) NO20005481L (de)
NZ (1) NZ507794A (de)
PL (1) PL199352B1 (de)
RU (2) RU2377302C2 (de)
SK (1) SK16172000A3 (de)
UA (2) UA77382C2 (de)
WO (1) WO1999057271A2 (de)
ZA (1) ZA200006123B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US7094875B2 (en) 2000-06-23 2006-08-22 Maxygen, Inc. Co-stimulatory polypeptides
US7183376B2 (en) 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
RU2317329C2 (ru) * 2005-05-04 2008-02-20 Дмитрий Валериевич Федосов Пара синтетических олигонуклеотидов-праймеров, используемых для выявления днк провируса лейкоза кошек эндогенного и экзогенного типа, и условия полимеразной цепной реакции с их использованием
WO2013102641A1 (en) * 2012-01-05 2013-07-11 Deutsches Krebsforschungszentrum Means and methods for treating or diagnosing idh1 r132h mutant-positive cancers
CN110184283A (zh) * 2019-04-30 2019-08-30 吉林农业大学 一种检测虎细小病毒的lamp-lfd试剂盒

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658669B1 (fr) * 1990-02-20 1992-07-24 Souriau & Cie Connecteur a verrouillage par levier.
KR100238712B1 (ko) * 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
AU7638894A (en) * 1993-09-03 1995-03-22 Miyuki Azuma B70(b7-2):ctla-4 bonding protein
ES2154738T3 (es) * 1994-10-03 2001-04-16 Us Gov Health & Human Serv Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
JP4025400B2 (ja) * 1997-04-16 2007-12-19 財団法人化学及血清療法研究所 新規免疫制御分子及びその製造方法

Also Published As

Publication number Publication date
JP2010252804A (ja) 2010-11-11
WO1999057271A9 (en) 2000-04-27
HUP0102806A2 (hu) 2001-11-28
PL345975A1 (en) 2002-01-14
ATE481485T1 (de) 2010-10-15
ZA200006123B (en) 2002-01-20
UA77382C2 (en) 2006-12-15
IL139371A (en) 2009-08-03
RU2377302C2 (ru) 2009-12-27
CZ20003935A3 (cs) 2001-12-12
EP1073741A2 (de) 2001-02-07
RU2263145C2 (ru) 2005-10-27
KR100869861B1 (ko) 2008-11-24
BR9910153A (pt) 2001-10-02
KR20010082542A (ko) 2001-08-30
NO20005481D0 (no) 2000-10-31
IL184202A (en) 2010-11-30
IL139371A0 (en) 2001-11-25
KR20040053251A (ko) 2004-06-23
IL184201A (en) 2010-11-30
PL199352B1 (pl) 2008-09-30
ES2352745T3 (es) 2011-02-22
JP2002513571A (ja) 2002-05-14
HK1034537A1 (en) 2001-10-26
CA2327539A1 (en) 1999-11-11
JP2010104369A (ja) 2010-05-13
UA87470C2 (ru) 2009-07-27
WO1999057271A2 (en) 1999-11-11
DE69942765D1 (de) 2010-10-28
NZ507794A (en) 2003-10-31
HUP0102806A3 (en) 2005-12-28
SK16172000A3 (sk) 2002-10-08
WO1999057271A3 (en) 2000-03-02
AU4070399A (en) 1999-11-23
RU2005108676A (ru) 2006-09-10
EP1073741B1 (de) 2010-09-15

Similar Documents

Publication Publication Date Title
AU4078599A (en) Expression vectors for stimulating an immune response and methods of using the same
ATE420112T1 (de) Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
AU2003278729A8 (en) Regulated bacterial lysis for gene vaccine vector delivery and antigen release
DE60041280D1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
NO20005481L (no) CD80-, CD86-, CD28- og CTLA-4-nukleinsyre og polypeptider fra katt
BR9802361A (pt) Derivado imunogênico detoxificado de b-toxina de clostridium perfringens ou um seu fragmento imunogênico, sequência de nucleotìdeos compreendendo um fragmento de dna mutante, bactéria clostriduim perfringensm sistema de expressão baseado em uma bactéria gram-positiva, vacina para combater infecção de clostridium perfrigens, processo para a preparação de b-toxina nativa de clostridium perfrigens, e, processo para preparação de uma vacina para combater infecção de clostridium perfrigens.
EP2172214A3 (de) Chlamydia-Antigene und entsprechende DNA-Fragmente sowie Verwendungen davon
WO2001046226A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
NO20005482L (no) Rekombinant virus og anvendelser derav samt vaksine som omfatter nevnte virus.
GB2409681A (en) Nucleic acid constructs for gene expression
IL149415A0 (en) Adjuvanted genetic vaccines
WO2000006742A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
MXPA01004353A (es) Antigenos de chlamydia y los correspondientes fragmentos de adn y usos de los mismos.
WO2000063242A8 (en) Chimeric lyssavirus nucleic acids and polypeptides
WO2001032204A3 (en) Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
AU2001289621A1 (en) Promoters for gene expression in caryopses of plants
WO2001036455A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
Tiollais et al. Method for the transformation of cells, particularly eukaryotes by a DNA originating from viruses of hepatitis, more particularly from virus of B viral hepatitis, and preparations containing the expression products of said DNAs
WO2000006743A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
SI1227840T1 (sl) Genetske vakcine z adjuvansom
WO2001036456A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2000006739A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application